<DOC>
	<DOC>NCT00919477</DOC>
	<brief_summary>To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).</brief_summary>
	<brief_title>Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Prostate cancer patients who have no history of receiving endocrine therapy (including surgical castration), and who plan to undergo Casodex® tablets monotherapy for not less than 12 months</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Casodex</keyword>
	<keyword>Monotherapy</keyword>
</DOC>